## oncoReveal<sup>™</sup>



## Multi-Cancer with CNV & RNA Fusion Panel

The **oncoReveal<sup>™</sup> Multi-Cancer with CNV & RNA Fusion Panel** is a combined DNA/RNA multi-cancer panel. The assay combines the DNA-based oncoReveal<sup>™</sup> Multi-Cancer v4 with CNV Panel with the oncoReveal<sup>™</sup> Multi-Cancer RNA Fusion v2 Panel allowing for joint sequencing. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp<sup>®</sup>) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.

ABL1	CDKN2A	FBXW7	GNAS	KIT •	NPM1	PTPN11	SRC
AKTI	CSF1R	FGFR1 •	HNF1A	KRAS •	NRAS	RAC1	STK11
ALK	CTNNB1	FGFR2	HRAS	MAP2K1	NTRK1	RB1	TP53
APC	DDR2	FGFR3 •	IDH1	MET 🗖	NTRK2	RET	VHL
ATM	EGFR	FLT3 •	IDH2	MLH1	NTRK3	ROS1	
BRAF	ERBB2	FOXL2	JAK2	MPL	PDGFRA•	SMAD4	
CCNE1	ERBB4	GNA11	JAK3	MYC	PIK3CA •	SMARCB1	
CDH1	EZH2	GNAQ	KDR •	NOTCH1	PTEN	SMO	

#### Variants and CNVs detected from DNA

CNVs detected and verified by NIST reference standard are indicated by 📕 CNVs can also be detected in genes indicated by ●

#### Fusions and expression insights detected from RNA Driver gene fusions (fusion partners not listed)

ALK	EGFR	FGFR2	MET	NTRK1	NTRK3	PPARG	RAF1	ROS1
BRAF	ERG	FGFR3	NRG1	NTRK2	PBX1	PRKACA	RET	TFE3

#### 3'/5' Expression Imbalance Ratio Assessed

ALK	FGFR3	NRG1	NTRK1	NTRK2	NTRK3	PBX1	RET	ROS1

### **Expression Control Genes**

HMBS TBP

#### Simple NGS library prep workflow

Maintain control of samples and results with tiled amplification that can be performed in-house by any NGS lab

#### Sensitive and robust chemistry

Achieve variant detection as low as 1% VAF<sup>+</sup> without UIDs<sup>‡</sup> even with limited input or poor sample quality

#### Reduced fullyloaded lab costs

Improve lab efficiency and reduce "no calls", repeat testing, and difficult interpretation decisions

## **Multi-Cancer with CNV & RNA Fusion Panel**

## oncoReveal<sup>™</sup>,



#### **Panel specifications**

	oncoReveal <sup>™</sup> Multi-Cancer v4 with CNV	oncoReveal™ Multi-Cancer RNA Fusion v2			
Enrichment chemistry	Multiplex PCR using tiled amplicons				
Number of pools	2 pools				
Number of genes/amplicons	60/341	18 genes and >80 partners, plus MET 14 exon skipping			
Number of targets	Hotspots in 60 genes; CNVs for 14 genes; -33.1kb total size	Fusions in 18 driver genes; expression for 11 genes			
Variant types	SNVs, small and medium indels, and CNVs	Fusion RNA transcripts			
Average amplicon size	143bp	120bp			
Recommended input range	5ng to 80ng DNA	20ng to 100ng RNA			
Sample types	DNA from tissue, blood; or FFPE	RNA from FFPE or tissue; cfRNA			
Mapping rate	99.23% ± 0.3%	n/a			
% on-target aligned reads	99.5% ± 0.1%	n/a			
Coverage uniformity (% targets with >0.2x mean coverage)	98.2% ± 0.7%	n/a			
Recommended reads per sample	~2 million paired-end reads				
Total assay time (from NA to sequencer)	<10.5 hours				

Mapping rate, percentage of on-target aligned reads, and coverage uniformity metrics are based on internal testing performed using reference standard materials

#### **Ordering information**

Pillar Custom Index Primers Kit D

Select the panel AND one of the index kit options listed below.

Panel		Part number
oncoReveal™ Multi-Cancer with CN\	/ and RNA Fusion Panel (48 reactions)	HNA-HS-1001-48
Pillar Index Kit options	Reactions	Part number
Pillar Custom Index Primers Kit A	32 Combinations 96 reactions	IDX-PI-1001-96

96 Combinations, 192 reactions

# TO ORDER OR LEARN MORE: pillarbiosci.com

For research use only. Not for use in diagnostic procedures. © 2022 Pillar Biosciences. Pillar<sup>®</sup>, SLIMamp<sup>®</sup>, PiVAT<sup>®</sup> and oncoReveal<sup>™</sup> are trademarks of Pillar Biosciences, Inc. Current as of 11.10.2023 | MK-0024-4 v1.1

## **PLLAR BIOSCIENCES**

IDX-PI-1004-192

Pillar Biosciences, Inc. 9 Strathmore Rd Natick, MA 01760 (800) 514-9307 info@pillarbiosci.com